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ABSTRACT
Background: Elderly patients with COVID-19 disease are at increased risk for adverse outcomes.
Current data regarding disease characteristics and outcomes in this population is limited.
Aim: To delineate the adverse factors associated with outcomes of COVID- 19 patients >75 years
of age.
Design: Retrospective cohort study.
Methods: Patients were classified into mild/moderate, severe/very severe, and critical disease
(intubated) based on oxygen requirements. The primary outcome was in-hospital mortality.
Results: 355 patients aged >75 years hospitalized with COVID-19 between March 19th and April
25th, 2020 were included. Mean age was 84.3 years. One-third of the patients developed critical
disease. Mean length of stay was 7.10 days. Vasopressors were required in 27%, with the highest
frequency in the critical disease group (74.1%). Overall mortality was 57.2%, with a significant
difference between severity groups (mild/moderate disease:17.4%, severe/very severe
disease:71.3%, critical disease: 94.9%, p<0.001). Increased age, dementia, and severe/very severe
and critical disease groups were each significantly associated with increased odds for mortality
while diarrhea was associated with decreased odds for mortality (OR:0.12, 95% CI:0.02-0.60,
p<0.05)]. None of the cardiovascular comorbidities were significantly associated with mortality.
Conclusion: Age and dementia are associated with increased odds for mortality in patients ≥75
years of age hospitalized with COVID-19. Those who require intubation have the greatest odds
for mortality. Diarrhea as a presenting symptom was associated with lower odds for mortality.
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INTRODUCTION
As of early January 2021, the coronavirus (SARS-CoV-2) pandemic remains a public health crisis,
affecting more than 84 million people globally and 20 million in the United States (US) alone. 1
Presentations range from an asymptomatic course to severe inflammatory reaction resulting in
acute respiratory distress syndrome (ARDS) and multi-organ dysfunction. 2

Older age, obesity, and other comorbid conditions are associated with higher rates of COVID-19
mortality.

3,4

The Centers for Disease Control and Prevention (CDC) reports that although

individuals older than age 65 comprise 17% of the total US population, they account for 31% of
COVID-19 infections, 45% of hospitalizations, 53% of intensive care unit (ICU) admissions, and
80% of deaths. 5 Similarly, a report from the Chinese Center for Disease Control and Prevention
evaluating more than 72,000 cases of COVID-19 reported an overall case fatality rate (CFR) of
2.3%. In contrast, the CFR was 8% in 70–79-year-olds and 14.8% in those ≥80 years old.

6

A

Chinese study of 201 patients found that older age is associated with a greater risk of developing
ARDS and of death. 7

Elderly patients may have one or more pre-existing medical conditions, which places them at
increased risk for developing severe forms of COVID-19 and even of dying from the disease.
Physiological changes that accompany aging, including altered immune response and multiple
age-related comorbidities (e.g., dementia), are associated with poorer outcomes in older patients.8

Very few studies have focused on the characteristics and outcomes of COVID-19 infection in the
elderly in the US; hence, data in this regard are limited. This retrospective single-center study aims
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to delineate the characteristics, risk factors, and outcomes among patients aged ≥75 years
hospitalized with COVID-19.

METHODS
Study Setting
A single-center, retrospective, observational analysis was performed at Maimonides Medical
Center, a 711-bed tertiary care teaching hospital in New York City. The Maimonides Medical
Center Institutional Review Board approved the study, qualified it as minimal risk research, and
waived the need for informed consent.

Patient Selection
We analyzed the clinical and demographic characteristics and outcomes of patients aged ≥75 years
admitted to Maimonides Medical Center with COVID-19 between March 19th and April 25th, 2020.
The method for diagnosis of SARS-CoV-2 infection was real-time reverse transcriptionpolymerase chain reaction (RT-PCR) testing of a nasopharyngeal sample. All patients included in
this study presented to our emergency department (ED) with either symptoms suggestive of
COVID-19 infection or had a history of exposure to a person with known COVID-19 infection.
Those who presented with symptoms and had a positive result as outpatient, were re-tested in our
emergency department to confirm COVID-19 infection. Patients who died within one day of being
admitted or during their ED stay prior to being admitted were excluded. Patients seen in the ED or
outpatient clinics that did not require hospitalization were also excluded.

Definition of Disease Severity
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Disease severity was determined by the amount of oxygen supplementation required throughout
the patient’s hospital course. Mild disease severity was defined as an oxygen saturation level >95%
on room air. Moderate disease severity was defined as requiring oxygen supplementation via nasal
cannula at rates of up to 5 L/min to maintain an oxygen saturation level of ≥95%. Severe disease
was defined as any patient with SARS-CoV-2 infection requiring oxygen supplementation via face
mask at rates up to 10 L/min to maintain an oxygen saturation level of ≥95%. The disease was
considered very severe when requiring oxygen supplementation via non-rebreather mask or highflow nasal cannula (HFNC) to maintain an oxygen saturation level of ≥95%. The disease was
deemed critical when intubation and mechanical ventilation were required.

Data Collection
Data collected included patient demographics, presenting symptoms, comorbidities, home
medications, initial vital signs upon admission, pertinent laboratory results, treatment received for
COVID-19, complications, and outcomes, including mortality and length of hospital stay (LOS).

Outcomes
The primary outcome was in-hospital mortality, described as death in hospital following the
diagnosis of COVID-19. The secondary outcome was LOS.

Statistical Analysis
Descriptive statistics of mean and standard deviation were used to describe continuous variables,
whereas frequencies and percentages were used to describe categorical variables. Skewed
variables were log-transformed. Troponin had values of 0; therefore, 0.01 was added to all values,
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which were then log-transformed. Analysis of variance compared continuous variables and
Pearson’s chi-square test compared categorical variables, except when the expected cell size was
<5, in which case the Fisher’s exact test was performed. Univariate logistic regression was
conducted for the outcome variable of mortality. Any variable that was statistically significant in
the univariate analysis for mortality was included in the multivariate analysis. Univariate linear
regression was conducted for the outcome variable of LOS. Any variable that was statistically
significant in the univariate analysis for LOS was included in the multivariate analysis. All pvalues were two-tailed. The alpha level for significance was set at p<0.05. IBM SPSS Statistics v.
26 (IBM, Armonk, NY) and Stata SE v. 15 (Stata, College Station, TX) were used for statistical
analyses.

RESULTS
Baseline Characteristics
There were 355 patients included in the study. The mean age was 84.3 years, and almost half were
female. Two-thirds were Caucasian and 7.6% were Hispanic. Hypertension (78.6%), diabetes
mellitus (33.8%), heart failure (26.2%), and coronary artery disease (26.2%) were the most
common comorbidities. There were 15.8% that were obese. Shortness of breath (58.9%), fever
(49.9%), and cough (41.1%) were the most common presenting symptoms. Table 1 shows the
baseline characteristics.

Management
Table 2 shows management and outcome variables. There were 33% that were intubated and 27%
required vasopressors, with the highest frequency for vasopressors in the critical disease severity
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group (74%). There were 10.1% that received hemodialysis and 9.9% received blood transfusions.
More than two-thirds received hydroxychloroquine (69.9%) and/or azithromycin (72.7%).
Prophylactic antibiotics were administered to 76.1%.

Complications
There were 10.1% diagnosed with bacteremia/fungemia, while <1% had either a cerebrovascular
accident or deep venous thrombosis. No statistical difference was found in the occurrence of deep
vein thrombosis/pulmonary embolism or cerebrovascular accident based on disease severity.
Bacteremia/fungemia were seen more often in patients with critical disease severity (19.8%).

Mortality and LOS
The overall mortality rate was 57.2%, with a significant difference between severity groups.
Patients with mild/moderate disease had mortality of 17.4%, those with severe/very severe disease
had mortality of 71.3%, and those with critical disease had the highest mortality of 94.9%
(p<0.001). The mean LOS was 7.10 days. This varied from 4.77 days in patients with
mild/moderate disease, 5.92 days for those with severe/very severe disease, to 9.1 days for those
with critical disease (p<0.001).

Dementia and Disease Outcomes
Table 3 shows comparisons between patients with and without dementia. Those with dementia
were older, had less diabetes, more severe/very severe disease, and less critical disease (i.e.,
intubated). Those with dementia had a greater percentage for mortality than those without
dementia (p=0.003). There was no difference for LOS between those with and without dementia.
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Both severe/very severe disease (p<0.001) and critical disease (p<0.001) were each significantly
associated with increased odds for mortality. Critical disease was significantly associated with
increased LOS.
Predictors of LOS
Table 4 shows linear regression analyses for LOS. In the multivariate analysis, female gender,
cough, severe/very severe disease, hemodialysis, blood transfusion, steroid use, prophylactic
anticoagulation, therapeutic anticoagulation, vitamin C, tocilizumab, and antibiotics for suspected
bacterial infection were each significantly associated with increased LOS. None of the
comorbidities, vital signs, laboratory values, and complication variables were significantly
associated with LOS.
Predictors of Mortality
Table 5 shows logistic regression analyses for mortality. In the multivariate analysis, increased
age, dementia, severe/very severe and critical disease were each significantly associated with
increased odds for mortality. Conversely, diarrhea was significantly associated with decreased
odds for mortality. None of the vital signs, laboratory values, treatment management, and
complication variables were significantly associated with mortality.

DISCUSSION
The current COVID-19 pandemic has affected the older population most severely. To our
knowledge, this study represents the largest US analysis focusing on elderly patients hospitalized
with COVID-19. Our findings indicate that even in very elderly patients that older age is associated
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with increased mortality. This corroborates previous studies that suggest that advancing age is a
risk factor for increased mortality in COVID-19 infection. 9-12

The overall mortality in our cohort was 57.2%. However, this percentage significantly varied
among disease severity levels where mild to moderate disease had mortality of 17.4% while critical
disease had mortality of 94.9%. Other studies report COVID-19 mortality rates for older patients
ranging from 20% to 97%. 9, 11, 13 This broad variation in mortality rates depends significantly on
admission criteria, disease severity and age cutoffs of the patients included in the individual
studies. As our study included only inpatients, we anticipated higher mortality rates than other
studies that included outpatients or patients who were seen in the emergency department and
discharged. Intubated patients (critical disease group) in our study had the highest mortality rate.
The mortality rate was similar to the 97% mortality rate found in the subgroup of older COVID19 patients who required intubation in another study. 13 This was likely due to a more severe disease
process in these patients leading to severe respiratory distress rather than intubation itself and its
complications. Hence, the decision to intubate in this elderly population should be individualized
based on the overall clinical picture as would be done in non-COVID patients.

Cardiovascular comorbidities are associated with worse outcomes in COVID-19 patients.

9, 14-18

As expected in a study focused on older patients, a higher percentage of hypertension, atrial
fibrillation, coronary artery disease, heart failure, and cerebrovascular disease were found in our
study as compared to reports that included younger patients.

13, 19

association for any of these comorbidities with mortality.
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However, we did not find any

COVID-19 patients with dementia had a higher mortality rate than those patients without
dementia. This contrasts with a study on elderly patients hospitalized with COVID-19 that
included 44% of patients with dementia. Although there was a numerically higher mortality in
patients with dementia (27% vs 20%), this was not statistically significant. 20 In a report from Italy
of 627 COVID-19 patients admitted to a geriatric service, patients with dementia had a mortality
rate of 62% as compared to 26% in those without the disease. 21 However, there was a difference
in age between the groups of 13.7 years which was statistically significant and could have
accounted for the difference in mortality. Interestingly, even though our study showed dementia
to be associated with higher mortality, less patients with dementia were in the critical disease
severity group. This could possibly be explained by a higher proportion of demented patients
undergoing palliative care and refusing aggressive interventions that would include intubation.

In our cohort, obesity was not associated with mortality. In contrast, a recent study in general
population found that obesity was associated with higher mortality. 10 It is possible that effect of
obesity differs by age group where the elderly that are obese are not associated with mortality.

Studies report the incidence rate of diarrhea in COVID-19 patients to range from 2–50%. 22-24 We
found diarrhea as a presenting symptom in 6.8% of patients, and its presence was associated with
decreased mortality. In a previous study by our group, diarrhea was associated with lower mortality
in COVID-19 patients with high oxygen requirements. 25 In contrast, another report found COVID19 patients with diarrhea, nausea, and vomiting to be more likely to develop ARDS requiring
mechanical ventilation as compared to patients without gastrointestinal symptoms. 26
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Our study has some limitations. First, we did not collect data on certain atypical symptoms, such
as delirium and altered mental status, which may be particularly relevant in the older population.
Second, we have no follow-up data on discharged patients to determine post-discharge mortality
and readmission rates. However, our focus was to characterize hospitalized patients and determine
their outcomes. Third, we did not include information regarding goals of care, which is of
paramount importance in the very elderly, especially with a disease process as lethal as COVID19. Although our study is one of the largest analyses to date focusing on the very elderly, further
research is needed in this population to address these topics.

CONCLUSION
Age and dementia are important risk factors for mortality in patients ≥75 years of age hospitalized
with COVID-19. Patients who require intubation have the greatest odds for dying. Patients who
reported diarrhea as a presenting symptom had lower mortality than those who did not.
Furthermore, although cardiovascular comorbidities are more frequent in the older population,
these comorbidities were not associated with mortality in our study.
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Table 1: Baseline characteristics

Variable

M (SD) or

M (SD) or

M (SD) or

M (SD) or

Frequency
(%)

Frequency
(%)

Frequency
(%)

Frequency
(%)

Whole
Sample

Mild/

Severe/

Critical

moderate

Very severe

(n=117)

(n=144)

(n=94)

(n=355)

p-value

Demographics
Age (years)

84.3 (6.51)

84.2 (6.54)

85.8 (6.69)

83.2 (6.15)

0.02

Female gender

164 (46.2)

69 (47.9)

46 (48.9)

49 (41.9)

0.51

Race

0.41

White

239 (67.3)

99 (68.8)

58 (61.7)

82 (70.1)

Black

45 (12.7)

21 (14.6)

13 (13.8)

11 (9.4)

Asian

41 (11.5)

12 (8.3)

16 (17.0)

13 (11.1)

Other

30 (8.5)

12 (8.3)

7 (7.4)

11 (9.4)

Ethnicity

0.35

Non-Hispanic

323 (91.0)

131 (91.0)

88 (93.6)

104 (88.9)

Hispanic

27 (7.6)

12 (8.3)

6 (6.4)

9 (7.7)

Unknown

5 (1.4)

1 (0.7)

0 (0.0)

4 (3.4)

56 (15.8)

16 (14.2)

12 (14.6)

28 (26.4)

Comorbidities
Obesity
Smoking

0.04
0.52

Never

94 (26.5)

38 (26.4)

20 (21.3)

36 (31.0)

Active

6 (1.7)

4 (2.8)

0 (0.0)

2 (1.7)

Former

30 (8.5)

12 (8.3)

8 (8.5)

10 (8.6)

Unknown

225 (63.4)

90 (62.5)

66 (70.2)

69 (59.0)

Hypertension

279 (78.6)

108 (75.5)

74 (78.7)

97 (82.9)

0.35

Diabetes mellitus

120 (33.8)

49 (34.3)

30 (31.9)

41 (35.0)

0.89

Cerebrovascular accident

37 (10.4)

9 (6.3)

13 (13.8)

15 (12.8)

0.11

Atrial fibrillation

78 (22.0)

25 (17.5)

23 (24.5)

30 (25.6)

0.23
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Heart failure

93 (26.2)

35 (26.1)

25 (28.1)

33 (30.6)

0.75

Chronic obstructive
pulmonary disease

34 (9.6)

14 (9.8)

11 (11.7)

9 (7.7)

0.61

Asthma

14 (3.9)

4 (2.8)

5 (5.3)

5 (4.3)

0.62

Deep vein
thrombosis/pulmonary
embolism

17 (4.8)

7 (4.9)

4 (4.3)

6 (5.1)

0.77

Chronic kidney disease

25 (7.0)

9 (6.3)

6 (6.4)

10 (8.5)

0.75

Coronary artery disease

93 (26.2)

41 (28.7)

21 (22.3)

31 (26.5)

0.56

Cancer

0.01

No

316 (89.0)

123 (86.0)

84 (89.4)

109 (93.2)

Active treatment

17 (4.8)

11 (7.7)

6 (6.4)

0 (0.0)

Past 5 years

21 (5.9)

9 (6.3)

4 (4.3)

8 (6.8)

88 (24.8)

27 (18.9)

39 (41.5)

22 (18.8)

<0.001

Fever

177 (49.9)

64 (45.1)

52 (55.3)

61 (52.1)

0.27

Cough

146 (41.1)

57 (40.1)

34 (36.2)

55 (47.4)

0.24

Anosmia

1 (0.3)

0 (0.0)

0 (0.0)

1 (0.9)

0.60

Ageusia

3 (0.8)

1 (0.7)

2 (2.1)

0 (0.0)

0.27

Myalgia

34 (9.6)

15 (10.6)

4 (4.3)

15 (12.8)

0.10

Nausea

16 (4.5)

9 (6.3)

4 (4.3)

3 (2.6)

0.34

Vomiting

14 (3.9)

9 (6.4)

4 (4.3)

1 (0.9)

0.06

Diarrhea

24 (6.8)

10 (7.0)

9 (9.6)

5 (4.3)

0.31

Shortness of breath

209 (58.9)

59 (41.5)

65 (69.1)

85 (72.6)

<0.001

Chest pain

18 (5.1)

8 (5.6)

6 (6.4)

4 (3.4)

0.56

Systolic blood pressure
[mmHg]

129.6 (24.68)

129.9 (22.53)

129.0 (24.62)

129.6 (27.30)

0.96

Diastolic blood pressure
[mmHg]

73.7 (19.07)

74.0 (16.82)

74.0 (19.90)

73.0 (21.00)

0.90

Heart rate [per minute]

93.8 (21.68)

91.1 (20.39)

95.4 (19.86)

95.9 (24.27)

0.15

Oxygen saturation

91.7 (8.08)

94.3 (5.47)

89.6 (9.52)

90.3 (8.67)

<0.001

Dementia
Presenting symptoms

Vital signs
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Respiratory rate [per minute]

24.7 (7.19)

21.4 (4.00)

26.3 (7.82)

27.3 (8.14)

<0.001

Note: M=mean, SD=standard deviation. Sample size for continuous variables less than 355 are:
Systolic blood pressure (n=353), Diastolic blood pressure (n=353), Heart rate (n=352), Oxygen
saturation (n=351), and Respiratory rate (n=353). Sample size for categorical variables missing
are: Obesity (n=54), Hypertension (n=1), Diabetes mellitus (n=1), Cerebrovascular accident
(n=1), Atrial fibrillation (n=1), Heart failure (n=24), Chronic obstructive pulmonary disease
(n=1), Chronic kidney disease (n=2), Asthma (n=1), Deep vein thrombosis/pulmonary embolism
(n=2), Coronary artery disease (n=1), Cancer (n=1), Dementia (n=1), Fever (n=2), Cough (n=3),
Anosmia (n=3), Ageusia (n=2), Myalgia (n=3), Nausea (n=2), Vomiting (n=3), Diarrhea (n=2),
Shortness of breath (n=2), and Chest pain (n=2).
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Table 2: Management and Outcomes
Variable

Laboratory values
White blood cell K/UL
Lymphocyte count
K/UL
Platelets K/UL

M (SD) or
Frequency
(%)
Whole
Sample
(n=355)

M (SD) or
Frequency
(%)
Mild/
moderate
(n=144)

M (SD) or
Frequency
(%)
Severe/
Very severe
(n=94)

M (SD) or
Frequency
(%)
Critical
(n=117)

p-value

9.4 (5.81)
12.5 (9.96)

8.6 (5.24)
13.8 (10.82)

10.0 (9.67)
11.5 (9.84)

9.7 (5.39)
11.9 (8.84)

0.01
0.17

208.5 (95.49)

214.4
(101.93)
12.1 (2.30)
142.6 (10.00)
1.9 (1.70)
20.7 (10.87)

194.2 (86.28)

0.10

12.5 (2.12)
138.7 (8.80)
2.1 (2.18)
22.4 (10.81)

0.23
<0.001
0.02
<0.001

Hemoglobin g/dL
Serum sodium mmol/L
Creatinine mg/dL
C-reactive protein
mg/dL (highest)
Ferritin ng/mL
(highest)
D-dimer ng/mL
(highest)
Lactate dehydrogenase
IU/L (highest)
Glomerular filtration
rate
Troponin ng/mL
(highest)
Procalcitonin ng/mL
(highest) [mean]
Alanine transaminase
IU/L [mean]
Aspartate transaminase
IU/L

12.3 (2.21)
139.3 (8.87)
1.83 (1.78)
18.5 (10.88)

216.7
(97.85)
12.1 (2.21)
137.7 (7.49)
1.6 (1.38)
13.2 (8.71)

1,107.9
(1,369.00)
5,810.0
(10,920.07)
561.8
(546.16)
44.2 (17.78)

863.3
(1,026.64)
3,257.2
(7,377.53)
403.9
(166.42)
47.6 (16.44)

944.5
(1,126.15)
7,812.1
(14,399.90)
501.6
(240.44)
41.5 (17.94)

1,478.8
(1,724.85)
6,933.7
(10,855.24)
762.9
(825.58)
42.3 (18.63)

0.01

1.0 (5.82)

0.3 (1.62)

1.0 (6.35)

1.6 (7.99)

<0.001

3.2 (6.90)

2.7 (7.61)

2.0 (2.50)

4.7 (8.10)

0.002

38.6 (63.12)

30.4 (35.16)

36.9 (53.06)

49.9 (89.91)

0.15

69.5 (111.85)

52.6 (54.04)

66.1 (69.88)

92.3 (171.89)

0.001

Intubation
Treatment management
Vasopressor
Hemodialysis
ECMO support
Blood transfusion
Hydroxychloroquine
Azithromycin
Ritonavir/lopinavir
Steroids

117 (33.0)

0 (0.0)

0 (0.0)

117 (100.0)

---

96 (27.0)
36 (10.1)
1 (0.3)
35 (9.9)
248 (69.9)
258 (72.7)
1 (0.3)
60 (16.9)

4 (2.9)
6 (4.3)
0 (0.0)
7 (5.1)
76 (54.3)
82 (59.0)
0 (0.0)
8 (5.8)

6 (6.4)
5 (5.4)
0 (0.0)
4 (4.3)
68 (72.3)
73 (77.7)
0 (0.0)
10 (10.6)

86 (74.1)
25 (21.4)
1 (0.9)
24 (20.5)
104 (88.9)
103 (88.0)
1 (0.9)
42 (36.2)

<0.001
<0.001
0.61
<0.001
<0.001
<0.001
0.60
<0.001
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0.02
<0.001
0.02

Prophylactic
anticoagulation
Therapeutic
anticoagulation
Convalescent plasma
Remdesivir
Vitamin C
Zinc
Tocilizumab
Antibiotics for
suspected bacterial
infection
Complications
Deep vein
thrombosis/pulmonary
embolism
Cerebrovascular
accident
Bacteremia/fungemia
Outcomes
Mortality
Length of stay (days)

232 (65.4)

84 (60.4)

64 (68.8)

84 (73.0)

0.09

90 (25.4)

28 (20.1)

25 (26.9)

37 (31.6)

0.11

7 (2.0)
7 (2.0)
350 (98.6)
105 (29.6)
11 (3.1)
270 (76.1)

1 (0.7)
0 (0.0)
42 (30.2)
37 (26.6)
0 (0.0)
82 (59.0)

1 (1.1)
0 (0.0)
36 (38.3)
25 (26.6)
2 (2.1)
78 (83.0)

5 (4.3)
7 (6.0)
53 (45.3)
43 (36.8)
9 (7.7)
110 (94.0)

0.14
<0.001
0.045
0.15
0.001
<0.001

2 (0.6)

1 (0.8)

1 (0.5)

0 (0.7)

0.73

3 (0.8)

1 (1.2)

1 (0.8)

1 (1.0)

1.00

36 (10.1)

5 (3.6)

8 (8.6)

23 (19.8)

<0.001

203 (57.2)
7.8 (7.10)

25 (17.4)
5.6 (4.77)

67 (71.3)
7.7 (5.92)

111 (94.9)
10.6 (9.14)

<0.001
<0.001

Note: M=mean, SD=standard deviation. Sample size for continuous variables less than 355 are:
White blood cell (n=351), Lymphocyte (n=317), Platelet (n=345), Hemoglobin (n=347), Serum
sodium (n=350) Creatinine (n=347), Ferritin (n=287), D-dimer (n=156), Lactate dehydrogenase
(n=298), Glomerular filtration rate-admission (n=346), Troponin (n=325), Procalcitonin (n=270),
Alanine transaminase-admission (n=313), and Aspartate transaminase-admission (n=313).
Sample size for categorical variables missing are: Vasopressor (n=6), Hemodialysis (n=6), Ecmo
support (n=6), Blood transfusion (n=6), Hydroxychloroquine (n=4), Azithromycin (n=5),
Ritonavir/lopinavir (n=6), Steroids (n=6), Prophylactic anticoagulation (n=8), Therapeutic
anticoagulation (n=6), Convalescent plasma (n=5), Remdesivir (n=5), Vitamin C (n=5), Zinc
(n=5), Antibiotics for suspected bacterial infection (n=5), Diagnosis of deep vein
thrombosis/pulmonary embolism (n=2), Diagnosis of cerebrovascular accident (n=7), and
Diagnosis of bacteremia/fungemia (n=9). Comparison between groups reports percentages only
for cases analyzed and does not include missing cases. Prophylactic anticoagulation included
Lovenox 40 mg (n=34, 9.6%) Lovenox 60 mg (n=73, 20.6%), Heparin (n=71, 20.0%), and Low
dose apixaban (n=54, 15.2%). Therapeutic anticoagulation included Lovenox (n=46, 13.0%),
Heparin drip (n=6, 1.7%), DOAC (n=35, 9.9%), and Coumadin (n=3, 0.8%). Laboratory values
are on admission unless otherwise specified.
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Table 3: Dementia analysis
Variable

Demographics
Age (years)
Female gender
Comorbidities
Obesity
Hypertension
Diabetes mellitus
Heart failure
Disease severity
Care-group
Mild/moderate
Severe/very
severe
Critical
Complications
Deep vein
thrombosis/
pulmonary
embolism
Cerebrovascular
accident
Bacteremia/
fungemia
Outcomes
Mortality
LOS (days)

No Dementia
M (SD) or
Frequency
(%)
(n=266)

Yes Dementia
M (SD) or
Frequency
(%)
(n=88)

p-value Dementia Mortality
Multivariate
OR (95% CI)
(n=88)

Dementia LOS
Multivariate
B (SE)
(n=88)

83.1 (6.26)
117 (44.0)

87.9 (5.96)
47 (53.4)

<0.001
0.12

1.03 (0.94, 1.13)
---

<0.001 (0.01)
---

45 (20.1)
211 (79.3)
100 (37.6)
72 (28.9)

11 (14.3)
68 (77.3)
20 (22.7)
21 (25.6)

0.26
0.68
0.01
0.56

----2.68 (0.68, 10.58)
---

-----0.04 (0.09)
---

116 (43.6)
55 (20.7)

27 (30.7)
39 (44.3)

1.00
9.81 (2.93, 32.80)***

Reference
0.05 (0.09)

95 (35.7)

22 (25.0)

53.71 (5.87, 491.38)***

0.24 (0.10)*

1 (0.4)

1 (1.2)

0.44

---

---

1 (0.4)

2 (2.3)

0.16

---

---

25 (9.6)

11 (12.8)

0.40

---

---

140 (52.6)
7.9 (7.49)

62 (70.5)
7.6 (5.83)

0.003
0.58

<0.001

Note: LOS=length of stay, M=mean, SD=standard deviation, OR=odds ratio, CI=confidence
interval, B=unstandardized beta, SE=standard error. *p<0.05, **p<0.01, ***p<0.001
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Table 4: Linear Regression for Hospital Length of Stay
Variable
Demographics
Age (years)
Female gender
Presenting Symptoms
Cough
Shortness of breath
Laboratory values
C-reactive protein
mg/dL
Ferritin ng/mL
(highest)
Disease severity
Mild/moderate
Severe/very severe
Critical
Treatment management
Vasopressor
Hemodialysis
Blood transfusion
Hydroxychloroquine
Azithromycin
Steroids
Prophylactic
anticoagulation
Therapeutic
anticoagulation
Convalescent plasma
Remdesivir
Vitamin C
Zinc
Tocilizumab
Antibiotics for
suspected bacterial
infection
Complications
Bacteremia/fungemia

Univariate
B (SE)

Multivariate
B (SE)

Multivariate
No Mortality
B (SE)

Multivariate
Yes Mortality
B (SE)

-0.01 (0.003)*
0.08 (0.04)#

-0.002 (0.003)
0.08 (0.04)*

--0.16 (0.06)**

--0.03 (0.05)

0.09 (0.04)*
0.12 (0.04)**

0.08 (0.04)*
-0.06 (0.04)

0.02 (0.06)
---

0.08 (0.05)
---

0.01 (0.002)**

---

---

---

0.12 (0.05)*

---

---

---

Reference
0.17 (0.05)**
0.27 (0.05)***

Reference
0.11 (0.05)*
0.10 (0.06)

Reference
0.27 (0.07)***
0.13 (0.19)

Reference
0.05 (0.08)
0.07 (0.08)

0.22 (0.05)**
0.27 (0.07)***
0.41 (0.07)***
0.22 (0.05)***
0.19 (0.05)***
0.33 (0.05)***
0.14 (0.04)**

-0.12 (0.06)
0.15 (0.07)*
0.24 (0.07)***
0.08 (0.06)
0.18 (0.05)**
0.18 (0.05)***

--0.02 (0.16)
0.33 (0.13)*
----0.13 (0.12)
0.26 (0.07)***

--0.14 (0.07)*
0.26 (0.07)***
----0.17 (0.06)**
0.18 (0.06)**

0.17 (0.05)***

0.23 (0.05)***

0.33 (0.09)***

0.18 (0.06)**

0.33 (0.15)*
0.47 (0.15)**
0.28 (0.04)***
0.27 (0.04)***
0.43 (0.12)***
0.31 (0.05)***

-0.18 (0.14)
0.12 (0.13)
0.12 (0.05)*
0.09 (0.05)
0.25 (0.11)*
0.12 (0.05)*

----0.16 (0.06)*
--0.41 (0.34)
0.13 (0.06)*

----0.15 (0.05)**
--0.19 (0.11)
0.08 (0.07)

0.30 (0.07)***

0.10 (0.06)

---

---

Note: B=unstandardized beta, SE=standard error. Multivariate whole sample analysis included
334 patients due to missing data. Multivariate no mortality subsample included 145 patients.
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Multivariate mortality subsample included 196 patients. C-reactive protein and Ferritin were not
included in the multivariate analysis due to missing data. For brevity purposes, many variables
not statistically significant in the univariate analyses are not shown in the table.
Multivariate whole sample adjusted R Square=0.38. Multivariate no mortality subsample
adjusted R Square=0.40. Multivariate mortality subsample adjusted R Square=0.33.
#p=0.05, *p<0.05, **p<0.01, ***p<0.001.
Laboratory values are on admission unless otherwise specified
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Table 5: Logistic Regression for Mortality Among Elderly COVID-19 Patients
Variable
Demographics
Age (years)
Comorbidities
Hypertension
Cerebrovascular accident
Heart failure
Dementia
Presenting symptoms
Diarrhea
Shortness of breath
Vital signs
Oxygen saturation
Respiratory rate [per minute]
Laboratory values
White blood cell K/UL
Serum sodium mmol/L
C-reactive protein mg/dL (highest)
Ferritin ng/mL (highest)
D-dimer ng/mL (highest)
Lactate dehydrogenase IU/L (highest)
Glomerular filtration rate (admission)
Troponin ng/mL (highest)
Aspartate transaminase IU/L
Disease severity
Care-group
Mild/moderate
Severe/very severe
Critical
Treatment management
Vasopressor
Hemodialysis
Blood transfusion
Hydroxychloroquine
Azithromycin
Steroids
Prophylactic anticoagulation
Therapeutic anticoagulation
Vitamin C
Antibiotics for suspected bacterial
infection

Univariate
OR (95% CI)

Multivariate
OR (95% CI)

1.05 (1.02, 1.09)**

1.10 (1.02, 1.18)*

1.83 (1.09, 3.05)*
2.56 (1.17, 5.59)*
1.75 (1.06, 2.88)*
2.15 (1.28, 3.60)**

1.83 (0.74, 4.56)
1.13 (0.31, 4.15)
2.36 (0.97, 5.74)
3.02 (1.19, 7.63)*

0.28 (0.11, 0.70)**
3.12 (2.01, 4.86)***

0.12 (0.02, 0.60)*
1.77 (0.76, 4.12)

0.94 (0.91, 0.97)***
772.43
(73.79, 8,085.45)***

0.97 (0.92. 1.01)
1.02 (0.96, 1.09)

3.30 (1.29, 8.44)*
1.03 (1.002, 1.05)*
1.08 (1.05, 1.11)***
1.75 (1.04, 2.93)*
2.36 (1.37, 4.08)**
36.60 (9.79, 136.92)***
0.98 (0.97, 0.996)*
3.17 (2.00, 5.02)***
1.005 (1.001, 1.01)*

3.44 (0.64, 18.54)
0.96 (0.91, 1.01)
--------1.00 (0.97, 1.03)
1.46 (0.63, 3.38)
---

1.00
11.81 (6.35, 21.98)***
88.06 (34.82, 222.70)***

1.00
11.00 (4.12, 29.36)***
54.25 (11.84, 248.44)***

24.44 (9.60, 62.19)***
3.49 (1.48, 8.19)**
2.32 (1.06, 5.12)*
4.26 (2.61, 6.95)***
3.50 (2.12, 5.77)***
4.07 (2.04, 8.15)***
1.75 (1.12, 2.75)*
1.62 (0.98, 2.66)
1.59 (1.02, 2.48)*
3.26 (1.93, 5.49)***

5.10 (0.82, 31.54)
5.78 (0.85, 39.16)
0.60 (0.11, 3.14)
1.85 (0.61, 5.60)
1.33 (0.42, 4.26)
0.62 (0.17, 2.30)
1.58 (0.64, 3.91)
--1.07 (0.45, 2.58)
0.55 (0.20, 1.50)
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Complications
Bacteremia/fungemia

3.46 (1.47, 8.13)**

0.72 (0.17, 3.08)

Note: OR=odds ratio, CI=confidence interval. Multivariate analysis included 289 patients due to
missing data. C-reactive protein, Ferritin, D-dimer, Lactate dehydrogenase, and Aspartate
transaminase at admission were not included in the multivariate analysis due to missing data. For
brevity purposes, many variables not statistically significant in the univariate analyses are not
shown in the table.
*p<0.05, **p<0.01, ***p<0.001
Laboratory values are on admission unless otherwise specified.
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